DHODH
What it does, reaction by reaction
This enzyme appears only in the regulation table, with no catalysed step recorded.
What accelerates and inhibits it
Regulation is pathway-specific, so each context is listed separately
Pyrimidine De Novo Synthesis (through to UMP, then CTP/dTMP)
Dihydroorotate availability and an oxidized mitochondrial CoQ pool
Leflunomide/teriflunomide, brequinar
No principal direct hormonal control; respiration and proliferative state influence flux.
Recent literature
Europe PMC · fetched just now · sorted by publication date
-
1
A label-free supramolecular nanoassembly triggers multi-organelle crosstalk-dependent metastasis inhibition via nuclear ROS-HDAC2 axis.
Wang R, Zou L, Mi D, Wang C, Song Z, Liu T, Zhao M, Wang D, Shi S. · 2026-09-20
open access unreviewed -
2
Ferroptosis in major depressive disorder: Molecular mechanisms, cellular vulnerability, and therapeutic opportunities.
Kong D, Duan R, Wang X, Wang X, Zhao J. · 2026-09-18
open access unreviewed -
3
Ferroptosis: significance to zoonotic diseases and therapeutic prospects.
Tian L, Cheng X, Ni J, Yang R, Ouyang W, Qi T, Liu Q, Wang D, Chen H, Wang X. · 2026-08-25
open access unreviewed -
4
Research progress of ferroptosis in gynecological diseases.
Chen W, Zhou W, Liu S. · 2026-06-19
open access unreviewed -
5
IGF2BP3 promotes gastric cancer progression by inhibiting ferroptosis through ETV4-mediated regulation of GCH1.
Li K, Wei H, Li F, Zheng Y, Zhou Y. · 2026-05-01
open access unreviewed -
6
PROTACs in cancer therapy: targeted degradation of GPX4, PARP and epigenetic regulators.
Periyasamy S, Jarrett T, Truong J, Skouta R. · 2026-03-26
cited 1× open access unreviewed -
7
FDA-approved IMPDH inhibitors synergize with ribavirin to inhibit respiratory syncytial virus by interfering with purine <i>de novo</i> synthesis.
Hu H, Wang Q, Ai Q, Zhou P, He Y, Ye Z, Ma K, Zhou M, Huang S, Wang L, Qi N, Xiao G, Wang S. · 2026-03-17
cited 3× open access unreviewed -
8
Antitumor activity and structure-activity relationship of poly (ADP-ribose) polymerase (PARP)-based dual inhibitors.
Yang C, Shang Y, Li X, Li J, Li H, Han J. · 2025-12-15
cited 1× open access unreviewed -
9
Reprogramming of cell death in gastric cancer: From molecular mechanisms to therapeutic potential (Review).
Liu M, Wu Z, Chen Q, Ni W, Chen Y, Zhu Y, Chen Y, Ma H, Lin Y. · 2026-09-25
open access unreviewed -
10
Tumor‑immune spatiotemporal co‑evolution: A new paradigm for understanding and overcoming therapy resistance in metastatic castration‑resistant prostate cancer (Review).
Yan L, Sun X, Su P. · 2026-09-25
open access unreviewed
External claims. These come from an index outside this database and are not checked against it. Treat them as leads.